Key Highlights
- Oxford BioDynamics Plc (LSE:OBD) fell 8.70% on 5 October 2026 following an update on its recent fundraise.
- On 1 October, the company extended the payment deadline for £250,000 owed by investor Vulpes Investment Management to 30 October 2026.
- The amount forms part of a £9.15 million placing of 9.15 billion shares at 0.1p, approved by shareholders on 26 August 2026.
- OBD said it has received all other net proceeds and that the delay will not affect its financial position or prospects.
- The company recently published research linking five fatigue conditions using its EpiSwitch 3D genomics platform.
Oxford BioDynamics Stock Drops 8.70% on Placing Update
Oxford BioDynamics Plc (LSE:OBD), the Oxford-based precision diagnostics company, saw its shares fall 8.70% on Monday 5 October 2026. The decline followed an announcement late on Thursday 1 October regarding an extension to the timetable of its recent placing. The shares trade at around a tenth of a penny, so small price changes translate into large percentage moves.
The company said it had agreed, at the request of investor Vulpes Investment Management, to extend the payment deadline for an outstanding £250,000 to 30 October 2026. Oxford BioDynamics, its nominated adviser Singer Capital Markets and Merlin Partners, as parties to the placing agreement, agreed to the extension. The independent directors, after consulting the nominated adviser, considered the amendment fair and reasonable for shareholders.
Why Oxford BioDynamics Is in Focus: Funding After a Large Placing
Investors have been closely watching LSE:OBD because of its funding position. On 10 August 2026, the company announced a £9.15 million fundraise through the placing of 9.15 billion new ordinary shares at 0.1p each. The placing was approved at a general meeting on 26 August, and the new shares were admitted to trading on AIM on 27 August. Oxford BioDynamics has stated that it has received all net proceeds except the outstanding £250,000.
Although the sum is small relative to the overall raise, any delay in payment from a placing participant tends to unsettle the market. Investors may worry about the strength of the investor base or whether further shares could come to market. The company has stressed that the matter will not impact its financial position or prospects, but the news was enough to prompt selling once trading resumed after the weekend.
EpiSwitch Platform and Commercial Progress
Oxford BioDynamics was spun out of Oxford University in 2007 to commercialise blood tests based on 3D genomics research. Its proprietary EpiSwitch platform analyses the three-dimensional architecture of the genome to identify biomarkers. The company currently has two commercially available tests: EpiSwitch PSE for prostate cancer detection and EpiSwitch CiRT, which assesses the likelihood of response to immune checkpoint inhibitor cancer therapies.
OBD has also developed a blood test for myalgic encephalomyelitis, also known as chronic fatigue syndrome, which demonstrated 96% accuracy in development. On 3 September 2026, the company announced research revealing a link between five fatigue conditions, which could broaden the application of its technology. In August 2026, it partnered with a Dubai clinic to expand into the UAE, and it has worked with a US sales partner to build its American presence.
Key Reasons Behind the 8.70% Fall in LSE:OBD
- Placing payment delay: the extension for £250,000 owed by one investor raised questions about the fundraise.
- Very low share price: at around 0.1p, small moves create large percentage swings.
- Heavy dilution legacy: the issue of 9.15 billion shares in August significantly enlarged the share base.
- Commercial traction: investors want evidence of rising test volumes and Revenue before rerating the stock.
- Sector caution: small-cap healthcare and diagnostics stocks have faced tough funding conditions.
Share Price Context
Oxford BioDynamics shares have traded in a wide 52-week range of around 0.08p to 0.75p, reflecting both moments of excitement, such as validation data from major pharmaceutical partners in the past, and periods of severe pressure linked to funding. The stock launched on AIM at 162p in 2016, underlining how much value has been lost through repeated fundraisings.
What Investors Will Watch Next
The immediate catalyst for LSE:OBD is receipt of the outstanding £250,000 by 30 October 2026. Beyond that, investors will look for updates on commercial uptake of EpiSwitch PSE and CiRT, progress toward launching the ME/CFS test, new partnerships and revenue growth. The company's financial year ends on 30 September, so a trading update or results statement could provide fresh insight into its performance and cash runway.






Please wait processing your request...